PCSK9 inhibition in PAD

被引：4
|
作者：
Huynh, Karina
机构：
来源：
NATURE REVIEWS CARDIOLOGY | 2018年 / 15卷 / 01期
关键词：
D O I：
10.1038/nrcardio.2017.204
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：4 / 5
页数：1
相关论文
共 50 条
  • [41] Lipids and PCSK9 inhibition in chronic kidney disease
    Schunk, S. J.
    Fliser, D.
    Speer, T.
    NEPHROLOGE, 2020, 15 (05): : 285 - 292
  • [42] PCSK9 inhibition in high-risk patients
    Zijlstra, Laurien E.
    Mooijaart, Simon P.
    Jukema, J. Wouter
    AGING-US, 2019, 11 (23): : 10791 - 10792
  • [43] PCSK9 INHIBITION AND AORTIC STENOSIS IN THE FOURIER TRIAL
    Bergmark, Brian
    O'Donoghue, Michelle
    Murphy, Sabina
    Kuder, Julia
    Ezhov, Marat V.
    Ceska, Richard
    Gouni-Berthold, Ioanna
    Jensen, Henrik Kjaerulf
    Tokgozoglu, Sadberk Lale
    Mach, Francois
    Huber, Kurt
    Gaciong, Zbigniew
    Lewis, Basil S.
    Schiele, Francois
    Jukema, Johan Wouter
    Pedersen, Terje
    Giugliano, Robert
    Sabatine, Marc Steven
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 2112 - 2112
  • [44] Inhibition of PCSK9: a novel approach for the treatment of dyslipidemia
    Stawowy, Philipp
    Just, Isabell A.
    Kaschina, Elena
    CORONARY ARTERY DISEASE, 2014, 25 (04) : 353 - 359
  • [45] PCSK9 Inhibition: Does Lipoprotein Size Matter?
    Si-Tayeb, Karim
    Cariou, Bertrand
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2015, 4 (11):
  • [46] PCSK9 INHIBITION IN AN IMMATURE MURINE MODEL OF SEPSIS
    Atreya, Mihir R.
    Wong, Hector R.
    SHOCK, 2019, 51 (06): : 53 - 54
  • [47] PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
    Blom, Dirk J.
    Dent, Ricardo
    Castro, Rita C.
    Toth, Peter P.
    VASCULAR HEALTH AND RISK MANAGEMENT, 2016, 12 : 185 - 197
  • [48] PCSK9 inhibition: ready for prime time in CKD?
    Mafham, Marion
    Haynes, Richard
    KIDNEY INTERNATIONAL, 2018, 93 (06) : 1267 - 1269
  • [49] BINDING OF PCSK9 TO CIRCULATING LDL: EFFECT OF PCSK9 MONOCLONAL ANTIBODIES ON THE LDL-BOUND PCSK9?
    De Stefano, D.
    Baragetti, A.
    Baragetti, A.
    Macri, N.
    Tavori, H.
    Fazio, S.
    Catapano, A. L.
    ATHEROSCLEROSIS, 2018, 275 : E101 - E101
  • [50] DYSLIPIDAEMIA Predicting the benefits and risks of PCSK9 inhibition
    Holmes, David
    NATURE REVIEWS ENDOCRINOLOGY, 2017, 13 (02) : 65 - 65
12345